Aptamer Group reports strong FY2025 growth and expands Optimer® portfolio

Aptamer Group

Aptamer Group plc (LON:APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, has announced that the Annual Report and Accounts for the year ended 30 June 2025 and Notice of its 2025 Annual General Meeting (AGM) were posted to shareholders today.

Aptamer will host its AGM at 11:00 GMT on 27 November 2025 at Windmill House, Innovation Way, York, YO10 5BR.  The AGM will be held in person only and there will be no new information presented at the meeting.

The results of voting on all resolutions at the AGM will be announced to the London Stock Exchange and the full results of the voting published on the Company’s website, as soon as practicable after the conclusion of the AGM.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:

Latest Company News

Aptamer Group retail offer raises £274,000, total fundraise reaches £4.5 million

Aptamer Group said its retail offer closed having raised about £274,000 before expenses. Subject to shareholder approval at the general meeting on 13 April 2026, the company expects to issue 45.7 million shares at 0.6p each, bringing total gross proceeds from the placing, subscription and retail offer to about £4.5 million.

Aptamer Group launches retail offer to raise up to £0.5 million at 0.6p per share

Aptamer Group plc has opened a UK retail offer through the BookBuild Platform to raise up to £0.5 million by issuing up to 83.3 million new ordinary shares at 0.6 pence each, with one warrant for every three shares subscribed.

Aptamer Group reports higher H1 revenue and launches £3.75m bookbuild

Aptamer Group said H1 2026 revenue rose 27% to £0.83 million, with progress across licensing, fee-for-service contracts and asset development. The company also announced a bookbuild expected to raise at least £3.75 million to extend cash runway into 2028.

Aptamer expands pipeline with targeted radiopharmaceutical initiative

Aptamer Group is developing a proprietary radiopharmaceutical pipeline using its Optimer® platform, supported by a partnership with Radiopharmium Ltd and early data indicating improved radioligand stability compared to existing approaches.

Aptamer and Metir advance real-time water pathogen detection programme

Aptamer Group has met Phase 1 technical objectives in its partnership with Metir, demonstrating the feasibility of integrating Optimer® binders into a continuous waterborne pathogen detection system.

Aptamer technology integrated into Twist’s new TrueAmp NGS Library Prep Kit

Aptamer Group has announced that Twist Bioscience Corporation has launched its TrueAmp Library Preparation Kit, incorporating Aptamer’s proprietary Optimer® binders to enable room-temperature stability in next-generation sequencing workflows.

    Search